162 related articles for article (PubMed ID: 15383442)
1. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease.
Duppenthaler A; Ammann RA; Gorgievski-Hrisoho M; Pfammatter JP; Aebi C
Arch Dis Child; 2004 Oct; 89(10):961-5. PubMed ID: 15383442
[TBL] [Abstract][Full Text] [Related]
2. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
Cabalka AK
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease.
Kristensen K; Stensballe LG; Bjerre J; Roth D; Fisker N; Kongstad T; Svendsen AL; Nielsen BW
Arch Dis Child; 2009 Oct; 94(10):785-9. PubMed ID: 19541682
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
Meberg A; Bruu AL
Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
7. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
[TBL] [Abstract][Full Text] [Related]
8. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
9. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC Epidemiologic Study.
Medrano C; Garcia-Guereta L; Grueso J; Insa B; Ballesteros F; Casaldaliga J; Cuenca V; Escudero F; de la Calzada LG; Luis M; Luque M; Mendoza A; Prada F; del Mar Rodríguez M; Suarez P; Quero C; Guilera M;
Cardiol Young; 2007 Aug; 17(4):360-71. PubMed ID: 17662160
[TBL] [Abstract][Full Text] [Related]
10. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
[TBL] [Abstract][Full Text] [Related]
11. Risk of Respiratory Syncytial Virus Infection in Cyanotic Congenital Heart Disease in a Subtropical Area.
Chiu SN; Shao PL; Chen HC; Lin MT; Huang LM; Kao FY; Huang SK; Wang JK; Wu MH
J Pediatr; 2016 Apr; 171():25-30.e1. PubMed ID: 26822618
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
13. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus infection and immunoprophylaxis for selected high-risk children in Central Australia.
Bolisetty S; Wheaton G; Chang AB
Aust J Rural Health; 2005 Oct; 13(5):265-70. PubMed ID: 16171499
[TBL] [Abstract][Full Text] [Related]
15. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.
Boyce TG; Mellen BG; Mitchel EF; Wright PF; Griffin MR
J Pediatr; 2000 Dec; 137(6):865-70. PubMed ID: 11113845
[TBL] [Abstract][Full Text] [Related]
16. Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.
Granbom E; Fernlund E; Sunnegårdh J; Lundell B; Naumburg E
Acta Paediatr; 2014 Aug; 103(8):840-5. PubMed ID: 24724913
[TBL] [Abstract][Full Text] [Related]
17. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
[TBL] [Abstract][Full Text] [Related]
18. Severe bronchiolitis and respiratory syncytial virus among young children in Hawaii.
Yorita KL; Holman RC; Steiner CA; Effler PV; Miyamura J; Forbes S; Anderson LJ; Balaraman V
Pediatr Infect Dis J; 2007 Dec; 26(12):1081-8. PubMed ID: 18043442
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus hospitalisation trends in children with haemodynamically significant heart disease, 1997-2012.
Chu PY; Hornik CP; Li JS; Campbell MJ; Hill KD
Cardiol Young; 2017 Jan; 27(1):16-25. PubMed ID: 27161255
[TBL] [Abstract][Full Text] [Related]
20. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
Saji T; Nakazawa M; Harada K
Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
